Literature DB >> 23179812

[Morphological alterations induced by preservatives in eye drops].

K K Huber-van der Velden1, H Thieme, M Eichhorn.   

Abstract

A large number of experimental and clinical investigations carried out recently have confirmed that the chronic application of eye drops induces significant cytological and histological impairment in ocular tissues. It is also generally accepted that preservatives are the components responsible for the observed changes. The most commonly used preservative in ophthalmology is benzalkonium chloride (BAC), which has a relatively high toxicity. Possible consequences of preservatives on the eye are chronic inflammation and subsequent fibrosis of the subconjunctiva and cell loss and structural changes in the conjunctival epithelium as well as in the epithelial and endothelial layers of the cornea. Frequently, dry eye symptoms occur or deteriorate during therapy. During the last few years new preservatives have been developed which seem to have fewer side effects; however, relatively little data are available with regard to these new substances. To minimize impairments of the eye, preservative-free formulations should be considered for therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23179812     DOI: 10.1007/s00347-012-2639-3

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  38 in total

1.  Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study.

Authors:  Hong Liang; Françoise Brignole-Baudouin; Aude Pauly; Luisa Riancho; Christophe Baudouin
Journal:  Adv Ther       Date:  2011-03-17       Impact factor: 3.845

2.  Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy.

Authors:  Richard A Lewis; Gregory J Katz; Mark J Weiss; Theresa A Landry; Jaime E Dickerson; John E James; Steven Y Hua; E Kenneth Sullivan; Dawnelle B Montgomery; David T Wells; Michael V W Bergamini
Journal:  J Glaucoma       Date:  2007-01       Impact factor: 2.503

3.  The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva.

Authors:  H Mietz; U Niesen; G K Krieglstein
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-09       Impact factor: 3.117

4.  Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells.

Authors:  Françoise Brignole-Baudouin; Luisa Riancho; Hong Liang; Christophe Baudouin
Journal:  Curr Eye Res       Date:  2011-11       Impact factor: 2.424

5.  Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells.

Authors:  M De Saint Jean; F Brignole; A F Bringuier; A Bauchet; G Feldmann; C Baudouin
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-03       Impact factor: 4.799

6.  In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost.

Authors:  Christophe Baudouin; Luisa Riancho; Jean-Michel Warnet; Françoise Brignole
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-09       Impact factor: 4.799

7.  Corneal and conjunctival changes caused by commonly used glaucoma medications.

Authors:  Robert J Noecker; Lisa A Herrygers; Raana Anwaruddin
Journal:  Cornea       Date:  2004-07       Impact factor: 2.651

8.  Ocular symptoms and signs with preserved and preservative-free glaucoma medications.

Authors:  N Jaenen; C Baudouin; P Pouliquen; G Manni; A Figueiredo; T Zeyen
Journal:  Eur J Ophthalmol       Date:  2007 May-Jun       Impact factor: 2.597

9.  Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery.

Authors:  D C Broadway; I Grierson; C O'Brien; R A Hitchings
Journal:  Arch Ophthalmol       Date:  1994-11

10.  Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy.

Authors:  J Charles Henry; James H Peace; Jeanette A Stewart; William C Stewart
Journal:  Clin Ophthalmol       Date:  2008-09
View more
  1 in total

1.  Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol.

Authors:  Saoirse McCrann; Ian Flitcroft; Niall C Strang; Kathryn J Saunders; Nicola S Logan; Samantha Szeyee Lee; David A Mackey; John S Butler; James Loughman
Journal:  HRB Open Res       Date:  2019-07-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.